Novo Nordisk Receives EU Approval for Hemophilia Drug
Novo Nordisk AS ADR NVO
News
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Novo Resources Releases Updated Corporate Presentation
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk Lifts Outlook as Rollout of Wegovy Weight-Loss Pill Continues — Update
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Stock Spotlight
Novo Resources Provides Business Update
Tibooburra Project Update: RC drilling to commence as Novo forms unincorporated Joint Venture with Manhattan Gold
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
United States